AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01572285 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham procedure using a non-penetrating needle
Study NCT00299429 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting and minimally invasive bypass surgery
Study NCT00299429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI with DES
Description: PCI with DES
Study NCT00287378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: omalizumab as per weight and IgE
Study NCT04059315 — intervention group
Intervention type: OTHER
Intervention: surgical treatment of facial bone fracture
Description: oral and maxillofacial injury patients admitted in our hospital. patients are getting treatment of soft and bone frature as follow soft tissue repaire, IMF, ORIF, consrvative.
Study NCT04316988 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography
Description: A real time 2D ultrasound evaluation was done over the trachea of the patient.
Study NCT01614691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1203
Description: Active
Study NCT01614691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02922049 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biopsies with histopathology
Description: All samples taken by biopsies will be correlated with the images taken by CLE.
Study NCT05709938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine and regular insulin versus NPH and regular insulin
Description: Patients with type 1 diabetes (T1DM) in group A received insulin glargine as basal therapy at night and regular insulin given prior to each main meal.~Patients in group B were given NPH and regular insulin in split and mix method in the morning and evening.
Study NCT05709938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine and regular insulin versus NPH and regular insulin
Description: Patients with type 1 diabetes (T1DM) in group A received insulin glargine as basal therapy at night and regular insulin given prior to each main meal.~Patients in group B were given NPH and regular insulin in split and mix method in the morning and evening.
Study NCT03346980 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Esophagogastroduodenoscopy
Description: All patients will be evaluated with both standard HD gastroscope and side-viewing duodenoscope; the latter to ensure proper visualization of the major papilla.
Study NCT02920242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin (Sandoz GmbH) tablet
Description: 200 mg tablet administered orally.
Study NCT02920242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin (Xifaxan)
Description: 200 mg tablet administered orally
Study NCT02920242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo tablet administered orally
Study NCT00577798 — intervention group
Intervention type: PROCEDURE
Intervention: contrast-enhanced magnetic resonance imaging
Description: Cardiac magnetic resonance imaging (cMRI) offers the unique advantage of being able to analyze both function and structure (myocardial changes in the form of both a functional decrease in ejection fraction and structural changes within the myocardium defined as delayed contrast uptake). Participants will have already received doxorubicin hydrochloride as standard therapy when undergoing chemotherapy for non-Hogdkin's lymphoma and Hogdkin's lymphoma.
Study NCT03825861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.
Study NCT04344561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural Positioning
Description: Investigators will adjust the positioning of hospital beds to assess improvements in oxygenation and respiratory status.
Study NCT02296983 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV-ZEBOV
Description: VSV-ZEBOV
Study NCT02380469 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Identification and provision of lacking information
Description: The intervention consists of an interview about the caregiver's responses (baseline measurement) to a list about 'lack of information' within 13 areas. For each area, the patient's nurse will enquire about what information is requested by the caregiver and the patient. Subsequently, the nurse provides the requested information. She may involve the doctor and arrange follow-up visits or phone calls until the need is covered
Study NCT02380469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identification and provision of lacking information
Description: The intervention consists of an interview about the caregiver's responses (baseline measurement) to a list about 'lack of information' within 13 areas. For each area, the patient's nurse will enquire about what information is requested by the caregiver and the patient. Subsequently, the nurse provides the requested information. She may involve the doctor and arrange follow-up visits or phone calls until the need is covered
Study NCT04133142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral nerve block, inter fascial nerve block
Description: regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. local anesthetic will be ropivacaine 0.5% posology according to the type of block
Study NCT03915093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational nursing protocol
Description: It is a booklet given to study group ,which contains Knowledge and practice about thoracoscopy, pre - post operative care and home care instructions
Study NCT03915093 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine hospital care
Description: The routine care given by physicians and nurses after thoracoscopic surgery
Study NCT03915093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine hospital care
Description: The routine care given by physicians and nurses after thoracoscopic surgery
Study NCT02156934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: paraurethral injection
Description: Paraurethral injection of muscle derived stem cell in patients with stress urine incontinency.
Study NCT03001817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: K-877
Study NCT03001817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: K-877
Study NCT03001817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Study NCT03001817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for K-877)
Study NCT03001817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for K-877)
Study NCT03001817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Fenofibrate)
Study NCT02835079 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tamoxifen
Study NCT03339843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Subjects will receive 200 mg of abemaciclib orally, two times a day, during cycles of 28 days each. An early FDG-PET/CT will be performed at cycle 1 day 14 to search for any new lesions.
Study NCT02131649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FCH PET/MRI Scan
Description: Patients will first undergo screening to ensure eligibility. If eligible, they will undergo a PET/MRI scan using 18F-FCH as the radiolabeled tracer. If prostate cancer is detected outside the prostate, patients may undergo a biopsy or follow-up 18F-FCH PET/MRI to confirm the results.
Study NCT02921841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: D*STAR
Study NCT02921841 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: D*HEALTH
Description: Digital general health promotion intervention. Time and attention matched intervention that targets health behaviors relevant to youth including exercise, nutrition, sleep, and smoking. Basic information about HIV and sexuality is also included.
Study NCT03501108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STOPPFrail deprescribing criteria
Description: STOPPFrail is a recently validated set of explicit deprescribing criteria devised specifically for use in older patients with advanced physical and /or mental morbidity such that the 1-year survival prognosis is likely to be poor. STOPPFrail-defined medications that appear on the patient's medication list are highlighted to the attending physician for his/her consideration for deprescribing i.e. removal from the medication list immediately or gradually as appropriate.
Study NCT03210337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-101 Topical Solution
Description: A-101 Topical Solution
Study NCT03210337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A-101 Vehicle Solution
Description: A-101 Vehicle Solution
Study NCT04565704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biopsy imaged by Optical imaging device.
Study NCT00785382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactulose Placebo
Study NCT00785382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Description: 150 mg Q12H x 2 doses
Study NCT02637037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)
Description: single fixed-combination dose tablets
Study NCT02637037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)
Description: single fixed-dose combination tablets
Study NCT02637037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)
Description: single fixed-dose combination tablets
Study NCT02637037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)
Description: single fixed-dose combination tablets
Study NCT00518089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.5% eye drops
Description: Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
Study NCT00518089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo eye drops
Description: Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
Study NCT04309097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital intervention
Description: REAP is a live-streaming platform that allows users to shoot short videos or photos related to their physical exercise or eye relaxation (e.g., staring out of the window) using their smartphones. The app has been optimised to be used with the iPhone or Android.~When taking a online course recess, students will have access to the REAP platform that allows them to watch stay-at-home workout videos developed by exercise physiologists. Students will then be asked to create their own workout videos/photos and upload them to the live-streaming platform. When upload is completed, students will receive instant motivational messages to increase their engagement with the program.
Study NCT04309097 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information-only intervention
Description: Participants will have access to online health information and stay-at-home workout videos.
Study NCT02164708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: The program progressively trained students in mindfulness of breathing, a form of meditation frequently employed secularly. The tutorials were held on campus five times weekly, led by a faculty member and a graduate student who were trained, experienced MM practitioners. The tutorials were one hour in duration and typically involved 40-45 minutes of guided MM followed by a question-answer period that addressed recent research findings. Program participation required attendance at one tutorial per week, and participants were encouraged to maintain autonomous MM practice.
Study NCT02689362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin
Description: 1 tablet per day
Study NCT02689362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 1 tablet per day
Study NCT02689362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Evogliptin
Description: 1 tablet per day
Study NCT02689362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Sitagliptin
Description: 1 tablet per day
Study NCT01048034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 100 mg / m(2) subcutaneously day 1-5 every 4 weeks for 6 cycles. Another three cycles will be given together with epo for those not responding to the first 6 cycles of Azacitidine
Study NCT01048034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoetin
Description: For those patients not responding to Azacitidine alone, the combination of Azacitidine and erythropoetin 60 000 U / week for 16 weeks will be given.
Study NCT01733680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amiloride
Description: Subjects will take either amiloride hydrochloride or placebo for 8 weeks.
Study NCT01733680 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral
Description: Each week of the study, subjects will complete the AISRS, BRIEF-A, and CGI to measure symptom improvement
Study NCT01733680 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral
Description: Each week of the study, subjects will complete the AISRS, BRIEF-A, and CGI to measure symptom improvement
Study NCT00476229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 1.5 mg/kg by vein on Days -11 to -7.
Study NCT00476229 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation
Description: 80 cGy daily on days -11 to -7 and -4 to 0.
Study NCT00476229 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Infusion
Description: PBSC infusion administered on day 0.
Study NCT00476229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 by vein on days -13, -6, 1, \& 8. Only those patients whose tumors express CD20 will receive Rituximab.
Study NCT02578303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vascular flow measurement by PC-MRI
Description: participants will undergo vascular flow measurement by PC-MRI at intra and extracranial levels
Study NCT02578303 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vascular flow measurement by PC-MRI
Description: participants will undergo vascular flow measurement by PC-MRI at intra and extracranial levels
Study NCT03399929 — intervention group
Intervention type: OTHER
Intervention: Post Acute Rehabiltation
Study NCT01348516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KM-023
Description: -KM-023 is dosed orally via 75 mg tablets. Study doses are 75 mg, 150 mg, 300 mg, and 600 mg QD for 1 (SAD) or 7 (MAD) days.
Study NCT01348516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for KM-023
Description: -Placebo for KM-023 is dosed orally via Placebo for KM-023 tablets. Study doses are 1, 2, 3, and 4 placebo tablets QD for 1 (SAD) or 7 (MAD) days.
Study NCT02100696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrozulimab
Description: Participants will receive 105 mg etrolizumab administered by SC injection Q4W.
Study NCT02100696 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo (matched with etrolizumab) administered by SC injection Q4W.
Study NCT01569893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-monitoring for patients with Dibetes mellitus
Description: Patients are equipped with a telemonitoring kit composed by a portable glucose meter and a gateway device for data transmission.~The patient can monitor his blood glucose level with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alert the reference clinician in case of worsening of symptoms.
Study NCT04033393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Game based dual-task training
Description: Participants in the experimental group will receive game based dual-task training with a treadmill
Study NCT04033393 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: Participants in the control group will receive treadmill training
Study NCT01620216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antitumor Drug Screening Assay
Description: Undergo pre clinical kinase inhibitor activity screening
Study NCT03735446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Standard chemotherapy (topoisomerase inhibitor)
Study NCT03735446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Standard chemotherapy (topoisomerase II inhibitor)
Study NCT03735446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Standard chemotherapy (anti-metabolite)
Study NCT00649870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir Hydrochloride Tablets 1000 mg
Description: 1000mg, single dose fed
Study NCT00649870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valtrex® Tablets 1000 mg
Description: 1000mg, single dose fed
Study NCT04125654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mNGS for pathogen detection
Description: This assay is a metagenomic test undertaken by BGI Genomics Co., Ltd. for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.
Study NCT02907996 — intervention group
Intervention type: DRUG
Intervention: Sofosbuvir
Description: 400 mg tablet administered orally once daily
Study NCT01620216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT01620216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Given PO
Study NCT01620216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01620216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Given PO
Study NCT01620216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01620216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Given PO
Study NCT01620216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib Hydrochloride
Description: Given PO
Study NCT01620216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO
Study NCT01620216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO
Study NCT01620216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT01620216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Given PO
Study NCT01620216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study NCT03866876 — intervention group
Intervention type: OTHER
Intervention: Eucapnic pH
Description: Collection of Biological marker (proposed by Racinet): eucapnic pH
Study NCT00597324 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary catheterisation
Description: Coronary angiography which may be followed by ad hoc percutaneous intervention if indicated clinically
Study NCT00597324 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronary catheterisation
Description: Coronary angiography which may be followed by ad hoc percutaneous intervention if indicated clinically
Study NCT00802256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpotomy
Description: removal of caries and cronal pulp tissue and then restoring of tooth
Study NCT01771289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel/cisplatin
Description: weekly docetaxel/cisplatin combined with radiation
Study NCT01771289 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: chemoradiation
Study NCT00080899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenretinide
Description: Given orally
Study NCT00080899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02872935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: .2mg of Glycopyrrolate will be given intravenously with the administration of the spinal dose
Study NCT02872935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 1ml of normal saline will be given intravenously with the administration of the spinal dose